REGN US75886F1075

Report

Delayed Nasdaq - 04:00:01 2023-03-24 pm EDT
820.00	USD		+2.22%

09:26a	Is Deutsche Bank the next one?
09:01a	Barclays Adjusts Price Target on Regeneron Pharmaceuticals to $915 From $815, Keeps Overweight Rating	MT
08:49a	BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $1,040 From $1,025, Maintains Outperform Rating	MT

Most relevant news about REGENERON PHARMACEUTICALS, INC.

09:01a	Barclays Adjusts Price Target on Regeneron Pharmaceuticals to $915 From $815, Keeps Ove..	MT
08:49a	BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $1,040 From $1,025, Ma..	MT
08:08a	Wells Fargo Adjusts Regeneron Pharmaceuticals Price Target to $915 From $860, Maintains..	MT
08:01a	Baird Adjusts Regeneron Pharmaceuticals Price Target to $800 From $756, Maintains Neutr..	MT
07:59a	Jefferies Upgrades Regeneron Pharmaceuticals to Buy From Hold, Adjusts Price Target to ..	MT
03/23	Gain in New-Home Sales Helps Equities Rise	MT
03/23	RBC Raises Regeneron Pharmaceuticals' Price Target to $833 From $802, Maintains Sector ..	MT
03/23	Piper Sandler Raises Regeneron Pharmaceuticals' Price Target to $850 From $800, Maintai..	MT
03/23	Baird Raises Regeneron Pharmaceuticals' Price Target to $800 From $756, Maintains Neutr..	MT
03/23	Raymond James Upgrades Regeneron Pharmaceuticals to Market Perform From Underperform	MT
03/23	Regeneron Pharmaceuticals, Sanofi Shares Rise on Trial Results of Respiratory Disease T..	MT
03/23	Regeneron Pharmaceuticals Up Nearly 7%, on Track for Record High Close -- Data Talk	DJ
03/23	Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	MT
03/23	Sector Update: Health Care	MT
03/23	EF Hutton Adjusts Regeneron Pharmaceuticals Price Target to $862 From $853, Maintains B..	MT

All news about REGENERON PHARMACEUTICALS, INC.

09:26a	Is Deutsche Bank the next one?
09:01a	Barclays Adjusts Price Target on Regeneron Pharmaceuticals to $915 From $815, Keeps Ove..	MT
08:49a	BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $1,040 From $1,025, Ma..	MT
08:08a	Wells Fargo Adjusts Regeneron Pharmaceuticals Price Target to $915 From $860, Maintains..	MT
08:01a	Baird Adjusts Regeneron Pharmaceuticals Price Target to $800 From $756, Maintains Neutr..	MT
07:59a	Jefferies Upgrades Regeneron Pharmaceuticals to Buy From Hold, Adjusts Price Target to ..	MT
06:23a	Analyst recommendations: Coinbase, Eastman Chemical, KB Home, Re..
03/23	ADRs End Mostly Higher, Tencent and Sanofi Trade Actively	DJ
03/23	New-Home Sales Data Help Lift Equities	MT
03/23	Gain in New-Home Sales Helps Equities Rise	MT

News in other languages on REGENERON PHARMACEUTICALS, INC.

10:25a	Compañías que se deben tener muy en cuenta por técnico este viernes en Wall Street
06:30a	USA-Les valeurs à suivre à Wall Street (actualisé)
03/23	Les données sur les ventes de logements neufs soutiennent les actions
03/23	La hausse des ventes de logements neufs favorise la progression des actions
03/23	Point marchés-Clôture mitigée pour les actions européennes avec les banques centrales
03/23	MÄRKTE EUROPA/Wenig verändert nach Fed - Sanofi gesucht mit Dupixent
03/23	Les actions de Regeneron Pharmaceuticals et de Sanofi augmentent à la suite des résulta..
03/23	MÄRKTE EUROPA/Börsen holen Verluste auf - Sanofi ziehen deutlich an
03/23	Wall Street monte avec l'espoir d'une pause dans les hausses de taux États-Unis
03/23	Wall Street monte avec l'espoir d'une pause dans les hausses de taux US

Analyst Recommendations on REGENERON PHARMACEUTICALS, INC.

09:01a	Barclays Adjusts Price Target on Regeneron Pharmaceuticals to $915 From $815, Keeps Ove..	MT
08:49a	BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $1,040 From $1,025, Ma..	MT
08:08a	Wells Fargo Adjusts Regeneron Pharmaceuticals Price Target to $915 From $860, Maintains..	MT
08:01a	Baird Adjusts Regeneron Pharmaceuticals Price Target to $800 From $756, Maintains Neutr..	MT
07:59a	Jefferies Upgrades Regeneron Pharmaceuticals to Buy From Hold, Adjusts Price Target to ..	MT

Press releases

03/23	Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by ..	GL
03/23	Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by ..	AQ
03/22	FDA Approves First-in-class Evkeeza® (evinacumab-dgnb) for Young Children with Ultra-ra..	GL
03/22	FDA Approves First-in-class Evkeeza® (evinacumab-dgnb) for Young Children with Ultra-ra..	AQ
03/21	Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medici..	GL

Analysis